Three-Drug Combination Extends Survival for Patients with Multiple Myeloma

For newly diagnosed patients with multiple myeloma who plan to delay autologous stem cell transplantation, adding the targeted therapy bortezomib (VelcadeĀ®) to a two-drug therapy improves how long they live compared with the doublet therapy alone, a new study has shown.

As part of first-line therapy, some patients with multiple myeloma may undergo a stem cell transplant. But because the procedure is time consuming and may cause serious side effects, patients may opt to delay it or to not have one at all.

Read Full Article Here >>